Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Biomarkers of response to gefitinib in non-small-cell lung cancer

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it


Prices may be subject to local taxes which are calculated during checkout


  1. Kris MG et al. (2003) Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149–2158

    Article  CAS  Google Scholar 

  2. Schiller JH et al. (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92–98

    Article  CAS  Google Scholar 

  3. Paez JG et al. (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497–1500

    Article  CAS  Google Scholar 

  4. Pao W et al. (2004) EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306–13311

    Article  CAS  Google Scholar 

  5. Castillo SS et al. (2004) Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. Cancer Res 64: 2782–2792

    Article  CAS  Google Scholar 

  6. Janne PA et al. (2004) Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, “Iressa”) on an expanded access study. Lung Cancer 44: 221–230

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to David P Carbone.

Ethics declarations

Competing interests

Dr Carbone has received fee-for-service payment as a consultant for both AstraZeneca and Genentech regarding proteomic analysis, but has no ongoing contract or retainer from them, and does not hold any stock or more direct conflict of interest with their drugs.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Carbone, D. Biomarkers of response to gefitinib in non-small-cell lung cancer. Nat Rev Clin Oncol 1, 66–67 (2004).

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing